| Literature DB >> 29200873 |
Li-Yu Wang1, Jia-Huan Li2, Xing Zhou1, Qi-Chang Zheng1, Xiang Cheng1.
Abstract
PURPOSE: To explore the potential of carbon nanoparticles (CNs) for the intraoperative detection of positive and negative lymph nodes in the treatment of colorectal cancer. PATIENTS AND METHODS: The clinical data of 470 patients undergoing surgical procedures for colorectal cancer from June 2010 to February 2013 were analyzed retrospectively. The patients were divided into the CN group (183 males and 161 females; mean age, 58.6±12.4 years), who were given a CN suspension, and the control group (78 males and 48 females; mean age, 59.1±12.2 years), who were not given a CN suspension. The operative time, blood loss, number of lymph nodes detected/positive lymph nodes, and prevalence of postoperative complications were compared between the two groups. Three years after surgery, 444 cases (327 cases in the CN group and 117 cases in the control group) were interviewed, with the remaining 26 cases lost to follow-up. With regard to tumor, node, metastasis staging, the survival and prevalence of recurrence in each group at 3 years were analyzed.Entities:
Keywords: colorectal neoplasms; curative resection; positive lymph nodes; prognosis
Year: 2017 PMID: 29200873 PMCID: PMC5702162 DOI: 10.2147/OTT.S146627
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Baseline characteristics of the study cohort
| Characteristics | CN group | Control group | Statistics | |
|---|---|---|---|---|
| Age (mean, years) | 58.6±12.4 | 59.1±12.2 | 0.964 | |
| Sex | ||||
| Male | 183 | 78 | 0.098 | |
| Female | 161 | 48 | ||
| Diameter of primary tumor (cm) | 3.96±1.73 | 4.24±1.66 | 0.702 | |
| Differentiation | 0.803 | |||
| Good | 15 | 6 | ||
| Moderate | 235 | 82 | ||
| Poor | 94 | 38 | ||
| Histology | 0.321 | |||
| Adenocarcinoma | 256 | 88 | ||
| Mucinous adenocarcinoma | 80 | 33 | ||
| Signet-ring cell cancer | 5 | 3 | ||
| Melanoma | 3 | 2 | ||
| TNM staging | 0.486 | |||
| I | 34 | 14 | ||
| II | 135 | 50 | ||
| III | 159 | 52 | ||
| IV | 16 | 10 |
Notes:
The p-value was calculated based on adenocarcinoma and the total prevalence of mucinous adenocarcinoma, signet-ring cell carcinoma, and melanoma. Data are mean ± SD for continuous variables and numbers for categorical variables.
Student’s t-test was used.
Abbreviations: CN, carbon nanoparticle; TNM, tumor, node, metastasis.
Intraoperative characteristics of the study cohort
| Characteristics | CN group | Control group | ||
|---|---|---|---|---|
| Operative time (min) | 115.71±1.01 | 123.33±41.65 | 1.76 | 0.81 |
| Blood loss (mL) | 50.68±28.09 | 63.67±49.40 | 2.29 | 0.02 |
| Number of lymph nodes detected | 9.13±6.30 | 8.89±6.11 | 0.39 | 0.70 |
Notes:
p<0.05.
Student’s t-test was used.
Abbreviation: CN, carbon nanoparticle.
Number of positive and negative lymph nodes
| Group | Positive | Negative | Total |
|---|---|---|---|
| Control | 166 | 954 | 1,120 |
| CN | 574 | 2,569 | 3,143 |
| Total | 740 | 3,523 | 4,263 |
Note: χ2=6.817, p=0.009.
Abbreviation: CN, carbon nanoparticle.
Postoperative complications
| Parameter | CN group, n (%) | Control group, n (%) |
|---|---|---|
| Postoperative fever of unknown origin | 6 (1.74) | 3 (2.38) |
| Wound infection/suppuration | 10 (2.91) | 2 (1.59) |
| Anal/stoma infection | 8 (2.33) | 2 (1.59) |
| Flatulence/stomach ache | 16 (4.65) | 10 (7.94) |
| Reduction/disappearance of flatulence | 6 (1.74) | 3 (2.38) |
| Abnormal abdominal mass | 2 (0.58) | 0 (0) |
| Anastomotic stoma fistula | 13 (3.78) | 2 (1.59) |
| Anastomotic bleeding | 1 (0.29) | 0 (0) |
| Gastric retention | 7 (2.03) | 2 (1.59) |
| Total | 69 (20.06) | 24 (19.05) |
Abbreviation: CN, carbon nanoparticle.
Three-year follow-up for stage II disease
| Items | Recurrence
| Metastasis
| Death
| |||
|---|---|---|---|---|---|---|
| CN group | Control group | CN group | Control group | CN group | Control group | |
| Yes | 1 | 3 | 11 | 3 | 34 | 8 |
| No | 131 | 46 | 121 | 46 | 98 | 41 |
| 2.600 | 0.033 | 1.784 | ||||
| 0.107 | 0.856 | 0.182 | ||||
Abbreviation: CN, carbon nanoparticle.
Three-year follow-up for stage III disease
| Items | Recurrence
| Metastasis
| Death
| |||
|---|---|---|---|---|---|---|
| CN group | Control group | CN group | Control group | CN group | Control group | |
| Yes | 4 | 3 | 11 | 2 | 24 | 4 |
| No | 149 | 47 | 142 | 48 | 129 | 46 |
| 0.480 | 0.218 | 1.872 | ||||
| 0.489 | 0.640 | 0.171 | ||||
Abbreviation: CN, carbon nanoparticle.